Description: Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need. The company focuses on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications is being investigated in two U.S. Phase 2b/3 clinical trials in acute respiratory deficiency due to COVID-19, as well as in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also involved in clinical development of RLF-100 for other indications in acute and chronic lung diseases. Relief Therapeutics Holding AG is based in Geneva, Switzerland.
Home Page: www.relieftherapeutics.com
Avenue de Secheron 15
Geneva,
1202
Switzerland
Phone:
41 44 723 59 59
Officers
| Name | Title |
|---|---|
| Mr. Paolo Galfetti | Chief Business Officer |
| Mr. Andrew J. Einhorn CPA | Chief Financial Officer |
| Mr. Giorgio Reiner | Chief Scientific Officer |
| Mr. Vincenzo Gallo | Head of Legal & Compliance |
| Ms. Melinda Keegan | Chief Human Resources Officer |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 1.2475 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0455 |
| Price-to-Sales TTM: | 5.9678 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 49 |